[144] Surgery Partners, Inc. SEC Filing
Form 144 summary for Surgery Partners, Inc. (SGRY)
This Form 144 notifies a proposed sale of 47,491 shares of common stock via UBS Financial Services Inc. on 08/08/2025 on NASDAQ. The filing reports an aggregate market value of $1,110,769 and lists total shares outstanding as 128,209,410. All listed shares were acquired via equity vesting from Surgery Partners on dated entries between 08/28/2022 and 03/02/2025. The table of vesting entries sums to the 47,491 shares to be sold. The filing indicates no securities sold in the past three months ("Nothing to Report").
Riepilogo del Modulo 144 per Surgery Partners, Inc. (SGRY)
Questo Modulo 144 comunica la proposta di vendita di 47,491 azioni ordinarie tramite UBS Financial Services Inc. il 08/08/2025 sul NASDAQ. L'atto riporta un valore di mercato complessivo di $1,110,769 e indica il totale delle azioni in circolazione pari a 128,209,410. Tutte le azioni elencate sono state acquisite tramite vesting azionario da Surgery Partners, con registrazioni datate tra il 08/28/2022 e il 03/02/2025. La tabella delle voci di vesting somma alle 47,491 azioni oggetto della vendita. Il deposito segnala nessuna vendita di titoli negli ultimi tre mesi ("Nothing to Report").
Resumen del Formulario 144 para Surgery Partners, Inc. (SGRY)
Este Formulario 144 notifica la propuesta de venta de 47,491 acciones ordinarias a trav茅s de UBS Financial Services Inc. el 08/08/2025 en el NASDAQ. La presentaci贸n informa un valor de mercado agregado de $1,110,769 y registra el total de acciones en circulaci贸n en 128,209,410. Todas las acciones listadas fueron adquiridas mediante vesting de acciones de Surgery Partners, con asientos fechados entre el 08/28/2022 y el 03/02/2025. La tabla de vesting suma las 47,491 acciones que se venden. La presentaci贸n indica ninguna venta de valores en los 煤ltimos tres meses ("Nothing to Report").
Form 144 鞖旍暯 鈥� Surgery Partners, Inc. (SGRY)
鞚� Form 144電� 08/08/2025鞐� NASDAQ鞐愳劀 UBS Financial Services Inc.毳� 韱淀暣 氤错喌欤� 47,491欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 韱奠頃╇媹雼�. 鞁犼碃靹滊姅 齑� 鞁滉皜 $1,110,769毳� 氤搓碃頃橂┌, 齑� 氚滍枆 欤检嫕 靾橂ゼ 128,209,410欤茧 旮办灛頃橁碃 鞛堨姷雼堧嫟. 旮办灛霅� 氇摖 欤检嫕鞚� Surgery Partners鞚� 欤检嫕 氩犾姢韺�(equity vesting)鞙茧 旆摑霅橃棃鞙茧┌, 旆摑 鞚检瀽電� 08/28/2022攵赌韯� 03/02/2025 靷澊鞚� 頃霌れ瀰雼堧嫟. 氩犾姢韺� 頃霌れ潣 頃╆硠電� 毵る弰 鞓堨爼鞚� 47,491欤检檧 鞚检箻頃╇媹雼�. 鞁犼碃靹滌棎電� 歆�雮� 3臧滌洈臧� 毵る弰頃� 歃濌秾 鞐嗢潓鞙茧 響滌嫓霅橃柎 鞛堨姷雼堧嫟 ("Nothing to Report").
R茅sum茅 du Formulaire 144 pour Surgery Partners, Inc. (SGRY)
Ce Formulaire 144 notifie une proposition de vente de 47,491 actions ordinaires via UBS Financial Services Inc. le 08/08/2025 sur le NASDAQ. Le d茅p么t indique une valeur de march茅 agr茅g茅e de $1,110,769 et mentionne le nombre total d'actions en circulation 脿 128,209,410. Toutes les actions list茅es ont 茅t茅 acquises par vesting d'actions (equity vesting) de Surgery Partners, avec des enregistrements dat茅s entre le 08/28/2022 et le 03/02/2025. Le tableau des 茅v茅nements de vesting totalise les 47,491 actions 脿 vendre. Le d茅p么t indique aucune vente de titres au cours des trois derniers mois ("Nothing to Report").
Formular 144 Zusammenfassung f眉r Surgery Partners, Inc. (SGRY)
Dieses Formular 144 meldet den geplanten Verkauf von 47,491 Stammaktien 眉ber UBS Financial Services Inc. am 08/08/2025 an der NASDAQ. Die Einreichung gibt einen aggregierten Marktwert von $1,110,769 an und listet die insgesamt ausstehenden Aktien mit 128,209,410. Alle aufgef眉hrten Aktien wurden durch Equity-Vesting von Surgery Partners erworben, mit Buchungen datiert zwischen 08/28/2022 und 03/02/2025. Die Tabelle der Vesting-Eintr盲ge ergibt die zu verkaufenden 47,491 Aktien. Die Meldung gibt keinen Verkauf von Wertpapieren in den letzten drei Monaten an ("Nothing to Report").
- None.
- None.
Insights
TL;DR: Routine insider sale notice; quantity and value disclosed, no recent prior sales reported.
The Form 144 is a standard compliance disclosure identifying an intended sale of 47,491 SGRY shares with an aggregate market value of $1,110,769 through UBS on 08/08/2025. The filing shows these shares were acquired entirely through equity vesting across multiple dates from 2022 to 2025, and the vesting entries listed total the shares to be sold. There are no reported securities sold in the past three months. From a trading-impact standpoint, the filing documents intent to sell but does not itself indicate market-moving information beyond the disclosed size and timing.
TL;DR: Disclosure meets Rule 144 notice requirements; reflects insider monetization of vested equity.
The notice complies with Rule 144 formalities by specifying broker, planned sale date, share count, aggregate value, and acquisition history. All shares flagged were received via equity compensation/vesting, and the filing explicitly states no other sales in the prior three months. This is a routine governance event documenting an insider sale plan rather than a corporate operational or governance change.
Riepilogo del Modulo 144 per Surgery Partners, Inc. (SGRY)
Questo Modulo 144 comunica la proposta di vendita di 47,491 azioni ordinarie tramite UBS Financial Services Inc. il 08/08/2025 sul NASDAQ. L'atto riporta un valore di mercato complessivo di $1,110,769 e indica il totale delle azioni in circolazione pari a 128,209,410. Tutte le azioni elencate sono state acquisite tramite vesting azionario da Surgery Partners, con registrazioni datate tra il 08/28/2022 e il 03/02/2025. La tabella delle voci di vesting somma alle 47,491 azioni oggetto della vendita. Il deposito segnala nessuna vendita di titoli negli ultimi tre mesi ("Nothing to Report").
Resumen del Formulario 144 para Surgery Partners, Inc. (SGRY)
Este Formulario 144 notifica la propuesta de venta de 47,491 acciones ordinarias a trav茅s de UBS Financial Services Inc. el 08/08/2025 en el NASDAQ. La presentaci贸n informa un valor de mercado agregado de $1,110,769 y registra el total de acciones en circulaci贸n en 128,209,410. Todas las acciones listadas fueron adquiridas mediante vesting de acciones de Surgery Partners, con asientos fechados entre el 08/28/2022 y el 03/02/2025. La tabla de vesting suma las 47,491 acciones que se venden. La presentaci贸n indica ninguna venta de valores en los 煤ltimos tres meses ("Nothing to Report").
Form 144 鞖旍暯 鈥� Surgery Partners, Inc. (SGRY)
鞚� Form 144電� 08/08/2025鞐� NASDAQ鞐愳劀 UBS Financial Services Inc.毳� 韱淀暣 氤错喌欤� 47,491欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 韱奠頃╇媹雼�. 鞁犼碃靹滊姅 齑� 鞁滉皜 $1,110,769毳� 氤搓碃頃橂┌, 齑� 氚滍枆 欤检嫕 靾橂ゼ 128,209,410欤茧 旮办灛頃橁碃 鞛堨姷雼堧嫟. 旮办灛霅� 氇摖 欤检嫕鞚� Surgery Partners鞚� 欤检嫕 氩犾姢韺�(equity vesting)鞙茧 旆摑霅橃棃鞙茧┌, 旆摑 鞚检瀽電� 08/28/2022攵赌韯� 03/02/2025 靷澊鞚� 頃霌れ瀰雼堧嫟. 氩犾姢韺� 頃霌れ潣 頃╆硠電� 毵る弰 鞓堨爼鞚� 47,491欤检檧 鞚检箻頃╇媹雼�. 鞁犼碃靹滌棎電� 歆�雮� 3臧滌洈臧� 毵る弰頃� 歃濌秾 鞐嗢潓鞙茧 響滌嫓霅橃柎 鞛堨姷雼堧嫟 ("Nothing to Report").
R茅sum茅 du Formulaire 144 pour Surgery Partners, Inc. (SGRY)
Ce Formulaire 144 notifie une proposition de vente de 47,491 actions ordinaires via UBS Financial Services Inc. le 08/08/2025 sur le NASDAQ. Le d茅p么t indique une valeur de march茅 agr茅g茅e de $1,110,769 et mentionne le nombre total d'actions en circulation 脿 128,209,410. Toutes les actions list茅es ont 茅t茅 acquises par vesting d'actions (equity vesting) de Surgery Partners, avec des enregistrements dat茅s entre le 08/28/2022 et le 03/02/2025. Le tableau des 茅v茅nements de vesting totalise les 47,491 actions 脿 vendre. Le d茅p么t indique aucune vente de titres au cours des trois derniers mois ("Nothing to Report").
Formular 144 Zusammenfassung f眉r Surgery Partners, Inc. (SGRY)
Dieses Formular 144 meldet den geplanten Verkauf von 47,491 Stammaktien 眉ber UBS Financial Services Inc. am 08/08/2025 an der NASDAQ. Die Einreichung gibt einen aggregierten Marktwert von $1,110,769 an und listet die insgesamt ausstehenden Aktien mit 128,209,410. Alle aufgef眉hrten Aktien wurden durch Equity-Vesting von Surgery Partners erworben, mit Buchungen datiert zwischen 08/28/2022 und 03/02/2025. Die Tabelle der Vesting-Eintr盲ge ergibt die zu verkaufenden 47,491 Aktien. Die Meldung gibt keinen Verkauf von Wertpapieren in den letzten drei Monaten an ("Nothing to Report").
FAQ
What does the SGRY Form 144 disclose?
How were the shares acquired that are being sold?
Does the filing report any recent sales of SGRY shares by the same person?
What broker is handling the proposed sale?
What is the total number of SGRY shares outstanding reported in the filing?
